麗珠醫藥(01513)一款阻滯劑獲內地批准開展一項適應症臨床試驗

　　麗珠醫藥(01513)(深:000513)宣布，收到國家藥品監督管理局核准，同意公司申報的JP-1366片開展「與適當的抗生素聯用以根除幽門螺杆菌」適應症臨床試驗。

　　公司稱，JP-1366片是一款創新鉀離子競爭性酸阻滯劑(P-CAB)。
《經濟通通訊社10日專訊》

【你點睇？】國民黨主席鄭麗文訪問大陸6日，料隨後與習近平會面。你認為在鄭麗文今次行程能否緩和两岸關係？► 立即投票

下一篇新聞︰10/04/2026 18:07 《中國要聞》工信部：加快構建高效統一ＡＩ芯片計算互聯生態

其他

10/04/2026 18:04 《中國要聞》中國互聯網協會倡平台尊重自主定價權，不強制要求…

10/04/2026 17:59 《香江策論－張憶東》戰火繼續，市場交易滯脹與避險：油飆金升美股債雙殺，港股賣空佔比高達22%

10/04/2026 17:48 《中國要聞》市監總局發布近百項國家標準，包括腦機接口、建築…

10/04/2026 17:39 《提振Ａ股》北交所擬設置風險警示股票單日買入數量上限

10/04/2026 17:39 《滬╱深股通》新易盛為深股通十大成交活躍股榜首

回頁頂

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。